CY1123571T1 - Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα - Google Patents
Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμαInfo
- Publication number
- CY1123571T1 CY1123571T1 CY20201101110T CY201101110T CY1123571T1 CY 1123571 T1 CY1123571 T1 CY 1123571T1 CY 20201101110 T CY20201101110 T CY 20201101110T CY 201101110 T CY201101110 T CY 201101110T CY 1123571 T1 CY1123571 T1 CY 1123571T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bupropione
- pharmaceutical
- adjustment
- plasma levels
- dextromethorphan plasma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Addiction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| PCT/US2015/028901 WO2016081027A1 (en) | 2014-11-21 | 2015-05-01 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123571T1 true CY1123571T1 (el) | 2022-03-24 |
Family
ID=56014366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101110T CY1123571T1 (el) | 2014-11-21 | 2020-11-24 | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP3763372A1 (enExample) |
| JP (5) | JP6602863B2 (enExample) |
| KR (7) | KR102253986B1 (enExample) |
| CN (2) | CN107205998A (enExample) |
| AU (4) | AU2015350559C1 (enExample) |
| CA (3) | CA3232022A1 (enExample) |
| CY (1) | CY1123571T1 (enExample) |
| DK (1) | DK3220909T3 (enExample) |
| ES (1) | ES2835304T3 (enExample) |
| HR (1) | HRP20201855T1 (enExample) |
| HU (1) | HUE052609T2 (enExample) |
| IL (4) | IL314982A (enExample) |
| LT (1) | LT3220909T (enExample) |
| MX (3) | MX2021001442A (enExample) |
| MY (1) | MY189466A (enExample) |
| PL (1) | PL3220909T3 (enExample) |
| PT (1) | PT3220909T (enExample) |
| RS (1) | RS61113B1 (enExample) |
| SG (2) | SG11201704066VA (enExample) |
| SI (1) | SI3220909T1 (enExample) |
| SM (1) | SMT202000639T1 (enExample) |
| WO (1) | WO2016081027A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| WO2016081027A1 (en) * | 2014-11-21 | 2016-05-26 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| CN114712358A (zh) * | 2019-01-07 | 2022-07-08 | 安泰赛普生物风投二代有限责任公司 | 用于治疗抑郁症的右美沙芬和安非他酮的组合 |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN114340608B (zh) * | 2020-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) * | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| IL298972A (en) * | 2013-11-05 | 2023-02-01 | Antecip Bioventures Ii Llc | Preparations containing dextromethorphan and bupropion or similar substances and their uses |
| US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| WO2016081027A1 (en) * | 2014-11-21 | 2016-05-26 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
-
2015
- 2015-05-01 WO PCT/US2015/028901 patent/WO2016081027A1/en not_active Ceased
- 2015-05-01 MY MYPI2017701828A patent/MY189466A/en unknown
- 2015-05-01 JP JP2017527254A patent/JP6602863B2/ja active Active
- 2015-05-01 DK DK15861189.7T patent/DK3220909T3/da active
- 2015-05-01 CN CN201580074124.7A patent/CN107205998A/zh active Pending
- 2015-05-01 IL IL314982A patent/IL314982A/en unknown
- 2015-05-01 KR KR1020187036244A patent/KR102253986B1/ko active Active
- 2015-05-01 CA CA3232022A patent/CA3232022A1/en active Pending
- 2015-05-01 LT LTEP15861189.7T patent/LT3220909T/lt unknown
- 2015-05-01 CN CN202010202397.8A patent/CN111297860A/zh active Pending
- 2015-05-01 KR KR1020217014289A patent/KR102376868B1/ko active Active
- 2015-05-01 PL PL15861189T patent/PL3220909T3/pl unknown
- 2015-05-01 KR KR1020257019724A patent/KR20250092295A/ko active Pending
- 2015-05-01 KR KR1020247005737A patent/KR102822654B1/ko active Active
- 2015-05-01 IL IL280905A patent/IL280905B2/en unknown
- 2015-05-01 PT PT158611897T patent/PT3220909T/pt unknown
- 2015-05-01 IL IL297349A patent/IL297349B2/en unknown
- 2015-05-01 KR KR1020227008513A patent/KR102524253B1/ko active Active
- 2015-05-01 KR KR1020237012943A patent/KR102640586B1/ko active Active
- 2015-05-01 SI SI201531421T patent/SI3220909T1/sl unknown
- 2015-05-01 SM SM20200639T patent/SMT202000639T1/it unknown
- 2015-05-01 RS RS20201405A patent/RS61113B1/sr unknown
- 2015-05-01 EP EP20193845.3A patent/EP3763372A1/en active Pending
- 2015-05-01 HR HRP20201855TT patent/HRP20201855T1/hr unknown
- 2015-05-01 KR KR1020177017050A patent/KR101931896B1/ko active Active
- 2015-05-01 CA CA2968371A patent/CA2968371C/en active Active
- 2015-05-01 ES ES15861189T patent/ES2835304T3/es active Active
- 2015-05-01 MX MX2021001442A patent/MX2021001442A/es unknown
- 2015-05-01 SG SG11201704066VA patent/SG11201704066VA/en unknown
- 2015-05-01 MX MX2017006653A patent/MX2017006653A/es unknown
- 2015-05-01 HU HUE15861189A patent/HUE052609T2/hu unknown
- 2015-05-01 CA CA3082645A patent/CA3082645C/en active Active
- 2015-05-01 AU AU2015350559A patent/AU2015350559C1/en active Active
- 2015-05-01 EP EP15861189.7A patent/EP3220909B1/en active Active
- 2015-05-02 SG SG10201911873XA patent/SG10201911873XA/en unknown
-
2017
- 2017-05-19 MX MX2023000320A patent/MX2023000320A/es unknown
- 2017-05-21 IL IL252417A patent/IL252417B/en active IP Right Grant
-
2019
- 2019-03-06 AU AU2019201548A patent/AU2019201548C1/en active Active
- 2019-10-09 JP JP2019185676A patent/JP6842129B2/ja active Active
-
2020
- 2020-11-24 CY CY20201101110T patent/CY1123571T1/el unknown
-
2021
- 2021-02-04 JP JP2021016211A patent/JP7226839B2/ja active Active
- 2021-02-15 AU AU2021200981A patent/AU2021200981B2/en active Active
-
2023
- 2023-02-02 JP JP2023014583A patent/JP2023041862A/ja active Pending
-
2024
- 2024-09-19 AU AU2024219871A patent/AU2024219871A1/en active Pending
-
2025
- 2025-05-07 JP JP2025077089A patent/JP2025105965A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| CY1124007T1 (el) | Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| BR112018012164A2 (pt) | anticorpos neutralizantes do vírus da imunodeficiência humana | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
| CY1123720T1 (el) | Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος | |
| CY1123844T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
| EP3534987A4 (en) | ADJUSTABLE DOSAGE ADMINISTRATION SYSTEM | |
| EA201890788A1 (ru) | Препараты оланзапина с замедленным высвобождением | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201991265A1 (ru) | Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат |